NYSE · ZTS
Healthcare · Drug Manufacturers - Specialty & Generic
$73.43
Down-$0.26 (-0.35%)
Updated Sep 16, 2026, 9:45 AM
SID Score
5.2/10
Composite research score
Smart Money
58/100
Neutral
Price performance
1M range · 20 trading sessions · Daily adjusted prices
ZTS closed at $73.43 after 20 trading sessions, down 0.72% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $72.91 | $73.7825 | $72.72 | $73.43 | 4.08M |
| Sep 14, 2026 | $74.20 | $74.82 | $73.485 | $73.67 | 3.77M |
| Sep 11, 2026 | $73.24 | $73.50 | $71.50 | $72.97 | 5.24M |
| Sep 10, 2026 | $73.07 | $73.40 | $72.35 | $72.86 | 5.41M |
| Sep 9, 2026 | $73.50 | $74.08 | $73.09 | $73.31 | 5.45M |
| Sep 8, 2026 | $74.80 | $75.10 | $73.48 | $73.56 | 5.66M |
| Sep 4, 2026 | $75.08 | $75.84 | $74.83 | $75.81 | 4.17M |
| Sep 3, 2026 | $77.01 | $78.00 | $74.74 | $76.29 | 3.13M |
| Sep 2, 2026 | $77.46 | $77.8479 | $75.88 | $76.17 | 4.48M |
| Sep 1, 2026 | $77.91 | $77.93 | $76.15 | $77.25 | 4M |
| Aug 31, 2026 | $77.00 | $77.21 | $75.62 | $77.10 | 5.81M |
| Aug 28, 2026 | $75.20 | $77.71 | $75.20 | $77.34 | 4.85M |
| Aug 27, 2026 | $76.57 | $76.9112 | $74.93 | $75.02 | 3.97M |
| Aug 26, 2026 | $76.82 | $78.7499 | $76.55 | $77.52 | 4.85M |
| Aug 25, 2026 | $76.65 | $77.45 | $75.88 | $77.29 | 3.48M |
| Aug 24, 2026 | $77.59 | $78.20 | $76.4805 | $77.17 | 4.07M |
| Aug 21, 2026 | $75.29 | $78.59 | $75.18 | $77.73 | 5.05M |
| Aug 20, 2026 | $76.10 | $77.2946 | $74.935 | $75.02 | 3.92M |
| Aug 19, 2026 | $74.63 | $77.46 | $74.62 | $76.68 | 5.22M |
| Aug 18, 2026 | $73.75 | $74.48 | $72.88 | $73.96 | 4.03M |
The latest Smart Investors Daily articles mentioning ZTS.
ZTS research
Company profile and research snapshot.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 25, 2026 | TD Cowen | Buy | — |
| Aug 20, 2026 | Stifel | Hold | — |
| Aug 11, 2026 | Citigroup | Buy | — |
| Aug 11, 2026 | BNP Paribas | Outperform | — |
| Aug 10, 2026 | Piper Sandler | Neutral | — |
No generated briefing is available yet.
Yahoo · Sep 8, 2026
Impax Asset Management, based in London and specializing in sustainable investing, released its Q2 2026 investor letter for the “Impax US Sustainable Economy Fund”. The letter can be downloaded here. The US Sustainable Economy portfolio outperformed the Russell 1000 in Q2 2026, with Institutional Class at 17.96%, Investor Class at 17.95%, and Class A at […]
Yahoo · Sep 3, 2026
Zoetis has significantly lagged the broader market over the past year, while analysts remain cautiously optimistic about its outlook.
Yahoo · Sep 2, 2026
PARSIPPANY, N.J., September 02, 2026--Zoetis Inc. (NYSE:ZTS) today announced that Kristin Peck, Chief Executive Officer, and Jay Saccaro, EVP, Chief Financial Officer and Chief Operating Officer, will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, 2026 at 1:50 p.m. ET.
ChartMill · Sep 1, 2026
Zoetis (ZTS) emerges from decent value screen with low P/E, high profitability, and strong returns. Growth moderates, leverage noted. Learn more.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ZTS.
